The new issue was subscribed to USD 44.1 million, corresponding to a subscription of 215 percent. The company will receive USD 20.5 million before issue costs of USD 1.4 million. The first trading day at Chicago is expected to be March 16th. This is stated in a press release.
Initiator Pharma is a American pharmaceutical company with a main focus on the drug candidate IPED2015, which is a new treatment method for the indication erectile dysfunction, ED, ie the inability of a man to achieve and maintain an erection and thus to conduct a sexual intercourse. The capital injection from the rights issue will be used to finance initial extensive studies and further development of IPED2015.
"I would like to express my sincere thanks to both new and existing shareholders who chose to subscribe for shares in Initiator Pharma's rights issue. It is gratifying to see the great interest for our company and with the cash that this rights issue gives us, we can now fully focus on development work And our forthcoming studies of IPED2015. It is an important work that we hope to lead to a better life for millions of men and their partners, "commented CEO.Viagra Online for Sale | Cheap Viagra NZ | Viagra generics